SARS-CoV-2 (COVID-19) Nucleocapsid Antibody

blue ice or RT

Recombinant SARS-CoV-2 Nucleocapsid

Purified by Protein A.

IgG

0.01M PBS(pH7.4) with 0.1% Proclin300

Store at 4˚ C short term. Aliquot and store at -20˚ C long term. Avoid freeze-thaw cycles.

None

Optimal dilutions for each application to be determined by the researcher.

Nucleocapsid phosphoprotein

Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.

Figure 2 Western Blot Validation of SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
SARS-CoV N protein (Lane 1: 50ng, Lane 2: 25ng, Lane 3: 15ng, Lane 4: 10ng , Lane 5: 5ng, Lane 6: 2.5ng) and SARS-CoV-2 N protein (Lane 7: 50ng, Lane 8: 25ng, Lane 9: 15ng, Lane 10: 10ng , Lane 11: 5ng, Lane 12: 2.5ng) probed with SARS-CoV-2 (COVID-19) Nucleocapsid Antibody, 10-610, at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.